← All candidates
No insider filings on record.
2 filings on record.
VVOSVivos Therapeutics, Inc.
NasdaqCM · Healthcare · $3.24M
$0.1611
+8.51% today
No insider filings on record.
Vivos Therapeutics, Inc. hasn't reported Form 4 activity yet.
Price · 1Y · dailyNo open-market activity in range
▸ hover a marker for the filing · drag to zoom · daily bars sharpen to 30-min on close ranges · 4 moves explained
Reverse-split 1×. When a company does a reverse split, the chart rewrites its old prices to look far bigger than they really were — so the high early prices here aren't what VVOS ever actually traded at. The drop is real, but those huge old numbers aren't.
AI brief · from the filings on this pagePro
The filings, the score and the setup on this page, read for you in about ten seconds — what the insiders did, and what stands against it.
Market cap
$3.24M
Float
19.1M
95% public
Short % float
Pro
Price / profit
—
not yet profitable
Price / future profit
—
Price / sales
0.2
Institutional stakes
▸ a holder crossing 5% files Schedule 13D if they intend to act on the company, 13G if they certify they will not · /A amends an earlier filing
2 filingsnewest first
The record
newest first
No insider transactions on file for VVOS yet.
Context
Wall St
$2.12 avg target
+1213.9% vs today · 3 analysts
▸ relayed analyst opinion, which tends to run optimistic — not our forecast or advice
Earnings · EPS vs forecast
2 of 4 quarters beat
Q2 '26−$0.31 act+$0.08
Q1 '26−$0.52 act−$0.07
Q4 '25−$0.58 act−$0.10
Q3 '25−$0.49 act+$0.02
Coverage
Vivos Therapeutics Inc (VVOS) (Q2 2026) Earnings Call Highlights: Revenue Surges 35% on ...GuruFocus.com · 4w agoVivos Therapeutics shares slide after Q2 revenue falls short of forecastsInvestorsHub · 08-17Vivos Therapeutics, Inc. Q2 2026 Earnings Call SummaryMoby · 08-15Vivos Therapeutics, Inc. (VVOS) Reports Q2 Loss, Lags Revenue EstimatesZacks · 08-14
The file stays open
2 filings on record.
The next one will be too.
▸ SEC EDGAR · FINRA · Nasdaq — public sources only · research, not advice